Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marie Schoumacher

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Current Oncology Reports|March 3, 2017
Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer TherapiesMarie Schoumacher, Mike Burbridge
European Journal of Cell Biology|July 9, 2010
Cytoskeleton networks in basement membrane transmigrationMarie Schoumacher, Daniel Louvard, Danijela Vignjevic
Methods in Molecular Biology (Clifton, N.J.)|July 23, 2013
Basement membrane invasion assays: native basement membrane and chemoinvasion assayMarie Schoumacher, Alexandros Glentis, Vasily V Gurchenkov, et al.
The Journal of Cell Biology|April 28, 2010
Actin, microtubules, and vimentin intermediate filaments cooperate for elongation of invadopodiaMarie Schoumacher, Robert D Goldman, Daniel Louvard, et al.
Advances in Cancer Research|July 16, 2008
Epithelial morphogenesis and intestinal cancer: new insights in signaling mechanismsSilvia Fre, Danijela Vignjevic, Marie Schoumacher, et al.
European Journal of Cell Biology|October 2, 2014
Conditional expression of fascin increases tumor progression in a mouse model of intestinal cancerMarie Schoumacher, Fatima El-Marjou, Marick Laé, et al.
Cells|January 23, 2020
AXL Controls Directed Migration of Mesenchymal Triple-Negative Breast Cancer CellsOlivier Zajac, Renaud Leclere, André Nicolas, et al.
Cancer Research|July 20, 2007
Fascin, a novel target of beta-catenin-TCF signaling, is expressed at the invasive front of human colon cancerDanijela Vignjevic, Marie Schoumacher, Nancy Gavert, et al.
British Journal of Cancer|October 28, 2015
Upcoming translational challenges for uveal melanomaNabil Amirouchene-Angelozzi, Marie Schoumacher, Marc-Henri Stern, et al.
Oncotarget|March 19, 2016
The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanomaNabil Amirouchene-Angelozzi, Estelle Frisch-Dit-Leitz, Guillaume Carita, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Current Oncology Reports|March 3, 2017
Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer TherapiesMarie Schoumacher, Mike Burbridge
European Journal of Cell Biology|July 9, 2010
Cytoskeleton networks in basement membrane transmigrationMarie Schoumacher, Daniel Louvard, Danijela Vignjevic
Methods in Molecular Biology (Clifton, N.J.)|July 23, 2013
Basement membrane invasion assays: native basement membrane and chemoinvasion assayMarie Schoumacher, Alexandros Glentis, Vasily V Gurchenkov, et al.
The Journal of Cell Biology|April 28, 2010
Actin, microtubules, and vimentin intermediate filaments cooperate for elongation of invadopodiaMarie Schoumacher, Robert D Goldman, Daniel Louvard, et al.
Advances in Cancer Research|July 16, 2008
Epithelial morphogenesis and intestinal cancer: new insights in signaling mechanismsSilvia Fre, Danijela Vignjevic, Marie Schoumacher, et al.
European Journal of Cell Biology|October 2, 2014
Conditional expression of fascin increases tumor progression in a mouse model of intestinal cancerMarie Schoumacher, Fatima El-Marjou, Marick Laé, et al.
Cells|January 23, 2020
AXL Controls Directed Migration of Mesenchymal Triple-Negative Breast Cancer CellsOlivier Zajac, Renaud Leclere, André Nicolas, et al.
Cancer Research|July 20, 2007
Fascin, a novel target of beta-catenin-TCF signaling, is expressed at the invasive front of human colon cancerDanijela Vignjevic, Marie Schoumacher, Nancy Gavert, et al.
British Journal of Cancer|October 28, 2015
Upcoming translational challenges for uveal melanomaNabil Amirouchene-Angelozzi, Marie Schoumacher, Marc-Henri Stern, et al.
Oncotarget|March 19, 2016
The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanomaNabil Amirouchene-Angelozzi, Estelle Frisch-Dit-Leitz, Guillaume Carita, et al.
Pageof 2